Company Overview and News

Cover Story: Hazy prospects for media companies

2018-10-04 theedgemarkets
ALTHOUGH Star Media Group Bhd is currently not in its best financial state, the fact that it is still turning a profit sets it a cut above other struggling Bursa Malaysia-listed media companies. Many print-based media firms, not only those in Malaysia, are trying hard to stay afloat.
4502 5754 MIAHF 6025 MS

Independent journalism seen to benefit media firms in long term

2018-10-01 theedgemarkets
Media sector Maintain neutral: The Malaysian Insight on Sept 6 reported, citing sources, that Prime Minister Tun Dr Mahathir Mohamad was mulling a ruling to cap political parties’ ownership of mainstream media companies at 10%.
4502 5754 6084 MIAHF

Union: Umno not serious in mending Utusan

2018-09-30 malaymail
KUALA LUMPUR, Sept 30 — The National Union of Journalists (NUJ) Peninsular Malaysia has called on other shareholders of Utusan Melayu (Malaysia) Bhd to save Malay daily Utusan Malaysia, claiming majority owner Umno has abandoned the paper and its staff.

Mazlan apologises to Anwar, defamation suit resolved

2018-09-28 malaymail
KUALA LUMPUR, Sept 28 — The defamation suit filed by Datuk Seri Anwar Ibrahim against former Barisan Nasional (BN) candidate for Permatang Pauh in the 13th general election Datuk Mazlan Ismail was resolved after the latter made an open apology to the PKR de facto leader at the High Court here today.

Utusan face legal action if VSS compensation not paid in lump sum

2018-09-24 theedgemarkets
PUTRAJAYA (Sept 24): Utusan Melayu (M) Berhad may face action under the Employment Act 1955 if it fails to pay compensation under the Voluntary separation Scheme (VSS) in one lump sum to employees who took up the scheme within 30 days of their date of termination.

Labour Dept: Utusan launching separation scheme for entire workforce

2018-09-24 malaymail
KUALA LUMPUR, Sept 24 — The financially distressed Utusan Melayu Bhd is offering all its over 1,300 workers a voluntary separation scheme, the Labour Department said.
5754 BSMAF 1818

Trading ideas: MNRB, NTPM, KESM, Utusan Melayu

KUALA LUMPUR: MNRB Holdings Bhd , NTPM Holdings Bhd , KESM Industries Bhd and Utusan Melayu (Malaysia) Bhd are among the stocks to watch on Monday, according to JF Apex Research.
5754 6459 5066 9334

KLCI to consolidate, immediate support at 1,800 points

2018-09-23 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI is expected to consolidate today with immediate support at 1,800 points.
5754 4863 5738 6459 UPBMF 5066 MYPRY MYTEF 5014 2089 9334

Labour Dept: Utusan plans to offer VSS to all 1,300 staff; payment by instalment

2018-09-22 theedgemarkets
KUALA LUMPUR (Sept 22): The Labour Department says Utusan Melayu (Malaysia) Bhd plans to offer voluntary separation scheme to 1,300 workers due to the company's financial problems and unstable condition, and that the company intends to make the VSS payment via instalments.

NUJ slams VSS offer to Utusan staff

2018-09-22 malaymail
KUALA LUMPUR, Sept 22 — The National Union of Journalists (NUJ) criticised Utusan Melayu (Malaysia) Berhad’s voluntary separation scheme (VSS) today as a dishonest, insincere and suspicious move.

MAHB, United Plantations, Utusan, TM, Binasat, KESM, NTPM, Country Heights and MNRB

2018-09-21 theedgemarkets
KUALA LUMPUR (Sep 21): Based on corporate announcements and news flow today, stocks in focus for Monday (Sep 24) may include the following: Malaysia Airports Holdings Bhd, United Plantations Bhd, Utusan Melayu (Malaysia) Bhd, Telekom Malaysia Bhd, Binasat Communications Bhd, KESM Industries Bhd, NTPM Holdings Bhd, Country Heights Holdings Bhd and MNRB Holdings Bhd.
UPBMF 5066 5088 2089 5014 9334 5754 4863 5738 6459 MYPRY MYTEF 1902

Utusan Melayu offers VSS to more than half its workers, say sources

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The Umno-controlled media group Utusan Melayu (Malaysia) Bhd is offering a voluntary separation scheme (VSS) to more than half of its 1,500 workers as part of its restructuring exercise to reduce overall costs due to the company's financial constraints, according to sources.
5754 BSMAF 1818

Lawsuits against Utusan reveal strange ad deals

2018-09-18 theedgemarkets
THE legal action by two Ancom Bhd-linked companies against Utusan Melayu (M) Bhd seeking the return of cash advances totalling RM18.5 million is raising eyebrows.

Utusan Malaysia journos set to picket over unpaid wages, says report

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 18): Journalists and photographers of cash-strapped Umno mouthpiece Utusan Malaysia are ready to stage a picket on being told that the company has run out of money, according to The Malaysian Insight (TMI).
5754 BSMAF 1818

Will curbs on politicians owning media target proxies too? Journalists’ group asks

2018-09-11 malaymail
PETALING JAYA, Sept 11 — Press groups have raised various concerns about the government’s proposal to cap share ownership in media organisations by political parties.
4502 5754 6084 MIAHF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...